CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial challenges standard treatment for debilitating nerve disease
Disease control Recruiting nowThis study compares a new drug called riliprubart against the standard treatment (IVIg) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes progressive weakness and numbness. Participants who are already receiving stable IVIg treatmen…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 04, 2026 01:51 UTC
-
New drug aims to stop nerve damage relapse in CIDP patients
Disease control Recruiting nowThis study is testing whether an investigational drug called DNTH103 can help control Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The trial will enroll 480 adults with CIDP to see if DNTH103 is better than a plac…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 01:50 UTC
-
New hope for nerve disorder: testing different strengths of immune therapy
Disease control Recruiting nowThis study is testing two different doses of an immune globulin (antibody) therapy given through an IV to see which works better for maintaining control of CIDP, a chronic nerve disorder. About 161 adults with CIDP who currently depend on treatment will receive either a lower or …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New Blood-Cleansing therapy tested for Hard-to-Treat nerve disorder
Disease control Recruiting nowThis study is testing a blood-filtering treatment called immunoadsorption for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune nerve disease. It will involve about 140 patients in Germany who haven't responded well to standard treatments lik…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: University of Ulm • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New drug trial offers hope for nerve disease patients
Disease control Recruiting nowThis study aims to see if a new intravenous drug called empasiprubart works as well as or better than the current standard treatment (IVIg) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness. For the first 6 months, par…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for nerve disease: major trial tests potential CIDP treatment
Disease control Recruiting nowThis study is testing whether an investigational medicine called empasiprubart is safe and can help adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. For the first 6 months, some participants will receive t…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New drug trial aims to control debilitating nerve disease
Disease control Recruiting nowThis study is testing whether an investigational drug called IMVT-1402 can help control Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare nerve disorder that causes weakness and disability. It will enroll 162 adults who are already on stable treatment for CIDP. Par…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Zapping muscles to move: new hope for those who Can't exercise?
Symptom relief Recruiting nowThis study is testing a special type of exercise for people with neuromuscular diseases (like ALS or muscular dystrophy) who often can't do regular workouts. It uses a suit that sends mild electrical signals to make muscles contract, aiming to improve strength, walking, balance, …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
Could your weight change your medication dose?
Knowledge-focused Recruiting nowThis study aims to understand how a person's body composition (like muscle and fat) affects the levels of immunoglobulin medication in their blood. It will enroll 20 adults with a nerve disorder called CIDP who receive this medication. Researchers will measure drug levels after p…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC